Payment overview · 2025
General Payments
$465.93
21 reported records · 13 companies
Healthcare provider profile · identity verified
Amit G Shah, MD
Allopathic & Osteopathic Physicians|Internal Medicine · INDIAN LAND, SC · NPI 1740288323
Verified facts
What the public records show
CMS Open Payments records show Amit G Shah, MD received $465.93 in general payments during 2025 across 21 reported records.
Amgen Inc. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $87.55 | 18.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.26 | 18.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.95 | 9.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.98 | 7.7% | 2 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $34.64 | 7.4% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $30.09 | 6.5% | 1 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $28.68 | 6.2% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $25.51 | 5.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.50 | 5.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.10 | 4.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.16 | 3.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.36 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.15 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $465.93 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $69.61 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.20 | 2 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $60.15 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $42.95 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.98 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.98 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.36 | 1 | 2025 |
Source payment records
|
|||||
| Persona Normalized: persona |
Device | Zimmer Biomet Holdings, Inc. | $28.68 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 234 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 182 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 178 | 49 |
| Lisinopril | Lisinopril | 157 | 42 |
| Metformin Hcl | Metformin Hcl | 132 | 37 |
| Losartan Potassium | Losartan Potassium | 118 | 35 |
| Gabapentin | Gabapentin | 103 | 30 |
| Omeprazole | Omeprazole | 94 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 21 |
| Alprazolam | Alprazolam | 67 | 14 |
| Simvastatin | Simvastatin | 67 | 23 |
| Trazodone Hcl | Trazodone Hcl | 60 | 15 |
| Carvedilol | Carvedilol | 56 | 15 |
| Furosemide | Furosemide | 56 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 52 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 21 |
| Montelukast Sodium | Montelukast Sodium | 49 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 17 |
| Metformin Hcl Er | Metformin Hcl | 45 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 17 |
| Eliquis | Apixaban | 43 | 12 |
| Azithromycin | Azithromycin | 42 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 14 |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | 12 |
| Finasteride | Finasteride | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 21 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 13 |
| Tacrolimus | Tacrolimus | 20 | suppressed |
| Nystatin | Nystatin | 19 | 11 |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Fluconazole | Fluconazole | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $465.93 · 21 records | Amgen Inc. | AIRSUPRA, BRUKINSA, EVENITY, FREESTYLE LIBRE 3, INSPIRE, KRYSTEXXA, Korlym, MOUNJARO, Persona, QULIPTA, UBRELVY, VRAYLAR, WaveWriter Alpha Prime 16, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error